79 results about "Renal tissue" patented technology

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

The invention discloses an application of PARP1PROTACA19 in preparation of a medicine for preventing and treating acute kidney injury, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: PARP1PROTAC A19 can reduce the expression level of PARP1 in HK2 cells and mice, reduce the levels of acute kidney injury markers KIM-1 and inflammatory factors of the HK2 cells and the mice, improve pathological changes of kidney tissues, and inhibit the occurrence of acute kidney injury. The traditional Chinese medicine composition has obvious prevention and treatment effects on acute kidney injury.

The invention discloses a diabetic nephropathy marker PARP1, a primer combination and application, and relates to the technical field of biology. The sequence of the primer combination is PARP1-F, and is as shown in SEQ ID NO. 1; 1, PARP1-R as shown in SEQ ID NO. 2; an internal reference primer beta-actin-F, which is as shown in SEQ ID NO. 17; an internal reference primer beta-actin-R is as shown in SEQ ID NO. 18. The invention finds that the expression of PARP1 in the kidney tissue of a patient with diabetic nephropathy is increased and is positively correlated with ACR (Activated Receptor). The invention also finds that PARP1 is related to podocyte damage, and knocking down PARP1 can relieve podocyte endoplasmic reticulum stress and apoptosis, and can reflect the progress of DKD to a certain extent.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Provided are a kidney-targeting delivery ligand, a conjugate, a composition, and a use thereof, relating to the technical field of oligonucleotide drugs. Provided is a delivery ligand suitable for kidney targeting. The delivery ligand and an active substance (such as an oligonucleotide) are covalently linked by means of a linker group to obtain an oligonucleotide conjugate. The oligonucleotide conjugate has affinity for a cell receptor present on a kidney target cell and can selectively and effectively reduce or inhibit the expression of a kidney target gene in a subject (such as human or animal). The provided oligonucleotide conjugate or pharmaceutical composition can effectively treat and / or prevent pathological conditions or diseases caused by aberrant expression of a specific gene in kidney tissue cells.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The invention relates to the technical field of surgical planning, in particular to a kidney tumor accurate resection path planning method and system based on three-dimensional modeling, and the method comprises the following steps: obtaining a kidney tissue tumor surface area, extracting a line segment towards a renal gate direction, extending a direction vector, constructing a passing guide line, and continuing a path to a compression direction; extracting a blood vessel crossing path section, dividing an interference area, adjusting the direction of a turning section, connecting a tumor and a renal gate, and generating a resection path planning result set. According to the method, by constructing a direction line segment set extending along a structure compression trend, advancing a path space trend segment by segment, combining a replacement mechanism of regions with inconsistent directions, depending on density division of crossing edge point segments, defining the distribution position of a traffic limited region, adjusting repeated turning segments through direction lines, and eliminating path fluctuation and turn-back interference, the traffic limited region is determined. The extending direction penetrates through the tumor center and is connected with the starting point path, the path track integrally keeps smooth extension, the space layout is more ordered, and the matching performance of the passing line segment structure is enhanced.

The invention discloses a renal interstitial fibrosis noninvasive grading model construction method and system based on multi-parameter MRI, and belongs to the technical field of medical image processing and artificial intelligence, and the method comprises the steps: S1, collecting multi-parameter MRI data of a renal interstitial fibrosis patient and a healthy contrast; s2, preprocessing the data; s3, performing cortex and medullary segmentation on the preprocessed data, and extracting features of the kidney tissue after segmentation; s4, fusing the extracted features, and constructing a comprehensive feature vector; s5, taking the fused comprehensive feature vector and a corresponding renal tissue pathological grading result as training data, inputting the training data into a deep learning model for training, and establishing a non-invasive grading model related to pathological grading; according to the multi-parameter MRI-based renal interstitial fibrosis non-invasive grading model construction method and system provided by the invention, non-invasive and accurate evaluation of the degree of renal interstitial fibrosis is realized by integrating multi-parameter MRI data and a machine learning algorithm.

The present disclosure provides an oligonucleotide conjugate, which is obtained by covalently linking a kidney-targeting polypeptide as a ligand to an oligonucleotide molecule capable of inhibiting the expression of a target gene via a linker group. The oligonucleotide conjugate has affinity to a cell receptor present on a kidney target cell, and can selectively and effectively reduce or inhibit the expression of a target gene in the kidney of a subject (e.g., a human or an animal). The oligonucleotide conjugate or pharmaceutical composition provided by the present disclosure can effectively treat and / or prevent a pathological condition or disease caused by abnormal expression of a specific gene in kidney tissue cells.

The invention belongs to the technical field of intelligent medical treatment and clinical decision, and particularly relates to an idiopathic membranous nephropathy prognosis prediction method and system based on deep learning and a cross-modal attention mechanism. In order to realize accurate prognosis evaluation of IMN, depth features of a kidney tissue pathological image are automatically extracted through a deep learning technology and are innovatively and deeply fused with clinical data of a patient, and finally a high-precision and explainable intelligent prediction model is constructed to guide clinical early intervention and individualized treatment decision.

The invention discloses a device for screening patients with minimal lesion type nephropathy and application of the device in screening the patients with minimal lesion type nephropathy. The device for screening the patients with minimal lesion type nephropathy comprises a substance for detecting 5-methylcytosine modification of miR-511-5p, or comprises a substance for detecting the expression quantity of an ENPP4 gene, a substance for detecting the expression quantity of an ENTPD1 gene, a substance for detecting the expression quantity of a DNMT1 gene and a substance for detecting the expression quantity of an RND3 gene. The invention finds that m5C modification of miR-511-5p in an MCD patient is down-regulated, key genes ENPP4, ENTPD1 and DMNT1 in peripheral blood of the MCD patient are further screened, expression of the key genes is down-regulated, and miR-511-5p affects lipid metabolism of renal tissues by down-regulating RND3. The device for screening the patients with the minimal lesion type nephropathy can be used for screening the patients with the minimal lesion type nephropathy.

The invention discloses a biomarker for detecting renal fibrosis, application and a system, and relates to the technical field of biological medicines. The invention relates to a biomarker for detecting renal fibrosis. The biomarker comprises urinary copper cyanin. Compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin has the following three advantages: 1, compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin is more sensitive to diagnosis of renal interstitial fibrosis and fibrosis severity; secondly, compared with traumatic renal tissue pathologic biopsy, urine is used as a diagnosis medium, so that true noninvasive effect can be realized, and no harm is caused to the body health of a patient; and thirdly, compared with detection means such as iconography, the method for detecting the urinary cupreocyanin marker is lower in cost, more flexible, high in timeliness and easier to popularize.

The present invention pertains to the technical field of biomedicine. Specifically disclosed is use of a substance for inhibiting the activity and / or expression of a CAPG gene or protein in the preparation of a product for treating renal fibrosis caused by kidney injury. First, research has found that CAPG is expressed at low levels in normal kidney tissues, while its expression level is increased in kidney tissues of patients with acute kidney injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic kidney disease, indicating that the expression of CAPG may be involved in the occurrence and development of renal fibrosis caused by kidney injury. Then, by means of constructing a CAPG knockout mouse model, it has been further found that knocking out CAPG can effectively alleviate the progression of renal fibrosis; and by means of culturing renal fibroblasts in vitro, it has been found that silencing or knocking down CAPG can inhibit TGF-β-induced activation of renal fibroblasts. The present invention is of great significance for the pathogenesis and treatment of kidney injury or renal fibrosis.

The invention relates to heterobacterium faecalis, in particular to application of heterobacterium faecalis DSM 13633 or a culture solution thereof in preparation of a medicine for preventing or treating diabetic nephropathy. The invention proves that the urine volume of a mouse with diabetic nephropathy can be reduced by the heterobacterium faecalis DSM 13633, and the levels of urinary albumin, urine creatinine and urea nitrogen can be reduced, so that the Allobacter sterilicis can be used for improving the renal function impairment induced by hyperglycemia. Meanwhile, the pathological evaluation of kidney tissue shows that the Allobaculum stericolicis can be used for improving the renal lesion of the hyperglycemia mouse. According to the present invention, with the application of the Allobaculum stericoranis, the mRNA expression level of M1 type macrophage markers (Il6, Il1beta, iNOS) in the diabetic mouse kidney tissue can be reduced, the mRNA expression level of M2 type macrophage markers (Arg1, Il10, CD206) can be increased, and the results show that the Allobaculum stericoranis can alleviate the hyperglycemia induced renal tissue inflammation state;

The invention discloses oral liquid with uric acid reducing and kidney protecting effects and a preparation method and application thereof, and belongs to the technical field of biology. The oral liquid with the effects of reducing uric acid and protecting kidney comprises the following raw materials: dendrobium officinale, American ginseng, taurine and a tea extract, and auxiliary materials comprise xylitol, potassium sorbate and purified water. Dendrobium officinale and American ginseng are decocted and purified and then are mixed with other raw materials. Experiments prove that the oral liquid not only can improve weight growth, reduce blood uric acid and blood urea nitrogen levels and blood xanthine oxidase activity, but also can improve kidney indexes of hyperuricemia mice, exert an anti-oxidation effect, inhibit inflammatory response and relieve pathological damage of renal tissues, thereby exerting the effects of reducing uric acid and protecting kidneys.

The application provides a biomarker combination for non-invasive diagnosis of IgA nephropathy, comprising IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application also provides an enzyme-linked immunoassay kit for auxiliary diagnosis of IgA nephropathy, which can jointly detect the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application further provides an evaluation method for case damage of kidney tissue, which is based on the joint detection of the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89 in a sample, calculates a multi-index prediction score, and sets an evaluation threshold to determine whether short glomeruli have pathological damage. When the biomarkers are used for auxiliary diagnosis of IgA nephropathy, the biomarkers not only have the characteristics of non-invasiveness, but also have higher sensitivity, higher specificity and higher stability, and have clinical application value.

The invention relates to a nano-selenium preparation for renal injury and a preparation method and application thereof, the nano-selenium preparation comprises a core and a shell, the core comprises selenium, the shell comprises distearoyl phosphatidyl ethanolamine-polyethylene glycol, and the shell wraps the surface of the core. The preparation method comprises the following steps: wrapping: respectively dissolving a raw material of the core and a raw material of the shell in a solvent to obtain a core material solution and a shell material solution; mixing the core material solution with the shell material solution, and wrapping the surface of the raw material of the core with the raw material of the shell to obtain a solution containing a nano-selenium preparation precursor; and preparing the nano-selenium preparation for renal injury: evaporating the solution containing the nano-selenium preparation precursor to dryness, and adding water to resuspend to obtain the nano-selenium preparation for renal injury. The nano-selenium preparation disclosed by the invention has a relatively good protection effect on AKI, has good kidney targeting property and biological safety, can effectively improve kidney functions, reduce pathological injury of kidney tissues and remarkably relieve mitochondrial injury and cell apoptosis, and has dose dependence.

The invention relates to the technical field of biological medicine, in particular to a biomarker related to early diagnosis of diabetic nephropathy and application of the biomarker. The invention discloses and verifies the application value of the TRPV2 protein as the biomarker for early diagnosis of diabetic nephropathy for the first time. Clinical queue research proves that compared with a healthy control group, the expression level of TRPV2 protein in proximal renal tubules of kidney tissues of DKD patients is remarkably increased and is continuously increased along with pathological grading progress, TRPV2 protein expression of III-IV-level DKD patients is remarkably higher than that of I-II-level DKD patients, and the TRPV2 protein expression of III-IV-level DKD patients is closely related to the degree of renal function impairment; meanwhile, the AUC of a working characteristic curve of a subject can reach 0.9077 to 0.9291. Therefore, the TRPV2 protein provided by the invention can accurately identify DKD patients and healthy people.

The present application relates to the field of drug delivery technology and chronic kidney disease treatment, in particular, a kidney tissue targeted chronic kidney disease treatment drug nano delivery system, which solves the problems of poor targeting, low bioavailability, obvious side effects of existing chronic kidney disease treatment drugs, and insufficient responsiveness and poor safety of existing nano delivery systems. The system comprises a double-responsive nano carrier, an anti-kidney fibrosis drug and a targeting mediation layer. The double-responsive nano carrier is based on methoxy polyethylene glycol modified chitosan-polylactic acid copolymer, contains pH-sensitive hydrazone bonds and redox-sensitive disulfide bonds, and has a core-shell structure. The surface of the carrier is covalently connected with CD13 receptor affinity peptides, and is coated with a polylysine modified hyaluronic acid targeting mediation layer. The drug is pirfenidone or mycophenolate mofetil, which is covalently combined with the carrier through a disulfide bond. The system can realize precise enrichment of kidney lesions and double-responsive controlled drug release, improve the treatment effect, and reduce systemic and local toxicity.

The invention provides a kidney pathological full-slice image glomerulus detection system, which relates to the technical field of medical image processing and comprises a preprocessing module, a detection module and a mapping output module. The preprocessing module is used for executing kidney tissue region extraction and image preprocessing of the kidney pathology full-slice image, and comprises the following steps: extracting a kidney tissue region mask from the kidney pathology full-slice image under a preset magnification, mapping the mask to a first resolution image, performing overlapping window-sliding slicing on the first resolution image, and screening effective patches; the detection module comprises a multi-scale feature interaction glomerular detection network and is used for performing glomerular detection on the screened patches and outputting a glomerular positioning prediction frame and a corresponding classification prediction result; and the mapping output module is used for restoring the patch-level detection result to the full-slice image coordinate system. According to the method, the robustness and precision of target detection can be effectively improved, and reliable technical support is provided for intelligent analysis and auxiliary diagnosis of kidney pathological images.

The invention discloses a compound for inhibiting C3 gene expression, a pharmaceutical composition and application thereof, and belongs to the technical field of small nucleic acid drug delivery. The oligonucleotide-conjugated compound and the pharmaceutical composition thereof can obviously inhibit the expression of C3 mRNA in animal liver tissues and C3 protein in serum; c3 deposition in the kidney tissue can be reduced, and the disease course with the C3 deposition in the kidney tissue can be improved; in SD (Sprague Dawley) rats and cynomolgus monkeys, the dose level of untoward effects (NOAEL) is 300 mg / kg. The oligonucleotide-conjugated compounds and pharmaceutical compositions thereof contribute to the alleviation, prevention and / or treatment of diseases or conditions mediated by C3 gene expression disorder.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The invention discloses application of mogroside V in preparation of an anti-renal fibrosis medicine, and belongs to the technical field of biological medicines. Experiments prove that the mogroside V can obviously improve the renal function of a mouse with renal fibrosis, and the serum creatinine and blood urea nitrogen levels are obviously reduced. Meanwhile, the compound can be used for effectively inhibiting the expression of fibrosis markers alpha-SMA and Fibronectin in renal tissues, and delaying the fibrosis process by up-regulating the expression level of an epithelial-mesenchymal transition marker E-cadherin. In addition, the mogroside V can also significantly reduce collagen deposition in kidney tissues, and plays a role in treating renal fibrosis. The traditional Chinese medicine composition has the advantages of safety, effectiveness, no side effect, good taste and the like when being used for preparing the anti-renal fibrosis medicine.